A demand for a buy-out puts you at a fork: agree a buy-back funded inside the bank's existing consents, or let the claim ripen toward a court-ordered exit that does not need the bank's agreement at all. Financing already in place narrows the negotiated route and adds a lender step before any price can be paid. This brief sets out both branches, what decides between them, and the deadline that actually runs.
What happens if you do nothing
Dutch law does not oblige a company, or its other shareholders, to buy someone out simply because they ask. Doing nothing preserves the status quo for now. It also has a cost: a shareholder met with silence, or with conduct that makes continued shareholding unworkable for them, has grounds to move the question from the boardroom to a court, whether by a petition against the co-shareholders or by opening inquiry proceedings before the Enterprise Chamber (Ondernemingskamer). Once that happens, the file sits with corporate law and governance rather than with negotiation, and the bank's consent stops being something you control on your own timetable.
The routes
| Route | What it takes | Time | Cost driver | What it gives you |
|---|---|---|---|---|
| Negotiated buy-back within existing headroom | Agreed price, board resolution, the distribution and balance-sheet tests satisfied, lender consent or waiver under the facility agreement | Weeks to a few months, set mainly by the lender's response time | Valuation work and any consent or waiver fee the facility provides for | A completed transfer, control kept in-house, no court record |
| Statutory exit petition against the co-shareholders | Showing conduct by the co-shareholders that makes continued shareholding unacceptable; a petition to the competent Dutch court, conducted with Dutch-qualified counsel of record | Well over a year to a first judgment, longer on appeal | Court fees and counsel's time across several rounds of pleadings, plus a court-ordered valuation in most cases | A court-set price and a transfer order that does not depend on the bank's cooperation, once final |
| Enterprise Chamber inquiry proceedings as leverage | Grounds to doubt proper policy or conduct within the company; a petition to the Enterprise Chamber, conducted with Dutch-qualified counsel of record | Interim measures can follow within weeks; the inquiry itself runs longer | Court fees and, if one is ordered, the cost of the court-appointed investigator | Interim relief that can force a decision, or findings that shift the negotiating position, but not a buy-out order by itself |
What decides between them
Start with what is actually broken. A dispute about price and process points toward negotiation; a dispute about trust and conduct points toward the exit petition or the inquiry route. Next, ask whether the bank will consent to funding a buy-back within a workable time: a lender under no pressure to move quickly can stall the negotiated route past the point where it still serves you. This is a different question from the one that arises when a shareholder is diluted by an issue they cannot fund; that scenario runs on capital, this one runs on exit, and the two are decided by different facts, set out in the sibling piece on a shareholder diluted by an issue they cannot fund. Finally, weigh confidentiality: a petition to a Dutch court is a public step; a negotiated buy-back is not.
The deadline that runs
There is no fixed statutory countdown that starts on the day the demand is made. What runs in parallel, and does have real dates attached, are the covenant test dates in the facility agreement, the notice period the facility requires before you can ask for a waiver, and any timetable written into the exit or drag clauses of the articles or the shareholders' agreement. Treat the facility's own calendar as the deadline until you have confirmed otherwise from the document itself.
Evidence to secure now
Pull the facility agreement and read the consent, negative pledge and distribution covenants before you answer the shareholder, not after. Pull the articles of association and any shareholders' agreement for exit or drag-along mechanics. Run the distribution and balance-sheet tests against the latest audited accounts, because a buy-back that fails either test is not available regardless of what the shareholder or the board would prefer. If the paying entity is a holding company funded through cross-border management fees rather than its own trading income, the cash-extraction constraints described in a holding company with no employees paying management fees cross-border apply on top of the covenant analysis. Where the file is still open and no signature has been requested yet, the checks set out in the before-signing report scenario cover the same ground in more detail.
Cost drivers
Valuation work is the first cost, whichever route you take. A lender consent or waiver fee, if the facility provides for one, sits on top of the negotiated route. The court petition route adds court fees and sustained counsel time across pleadings and any court-ordered expert valuation. Separate from all of this is a cost that is easy to miss: a buy-back completed without satisfying the distribution test exposes the directors who approved it to personal liability, on the same footing set out in the piece on enforcing director liability once a filing failure is established. That risk does not disappear because the shareholder is pressing for speed.
What we would do in the first week
Pull the facility agreement and mark every clause that touches consent, negative pledge, and distributions. Pull the articles and any shareholders' agreement for exit provisions. Run the distribution and balance-sheet tests against the latest accounts before making any commitment to the shareholder. Open a controlled, written channel with the lender before you respond, rather than after. Decide, on the answers to those four steps, whether this is a negotiation to manage or a petition to prepare for.
What this does not cover
- The tax treatment of the buy-back price or of the transaction structure chosen to fund it.
- The separate route where the company itself, rather than the co-shareholders, is asked to acquire its own shares, which runs on different rules again.
- Shareholders based outside the Netherlands and any cross-border enforcement of a resulting order.
- Valuation methodology or how a court-appointed expert is instructed.
Questions
Can the bank block a shareholder buy-out?
The bank cannot block the shareholder's underlying claim, but it can block the funding route: if the facility requires consent for a distribution or a repurchase, a buy-back cannot lawfully complete without that consent or a waiver, whatever the shareholder and the board agree between themselves.
What happens if the shareholder goes straight to the Enterprise Chamber?
Enterprise Chamber inquiry proceedings can produce interim measures within weeks and put the company's conduct on the public record, but the proceedings themselves are aimed at policy and governance, not at ordering a buy-out; they change the leverage in a negotiation more often than they end it.
Does the company have to buy back its own shares, or can it insist the other shareholders do it?
Dutch law treats a repurchase by the company and a transfer to the co-shareholders as different transactions with different tests, and which one is available depends on the articles, the shareholders' agreement, and whether the distribution and balance-sheet tests are met; neither is the automatic default.
Written by Hugo Steenbergen, corporate law and governance. She works on shareholder disputes where a bank or other secured creditor sits inside the same structure.
Where the position needs mapping before you respond to the shareholder, a structured note on Enterprise Chamber proceedings sets out the procedural options in more detail, and a structure report maps the group's holding chain and existing security against the facility agreement itself.
Last legal review: 2026-10-05